Tuesday, August 11, 2026

Shocking Truth About Summer Workouts: Rhabdo Risks Revealed

Engaging in high-intensity strength training over a short period can strain muscles and lead to rhabdomyolysis.

Just Allow Espionage: The Ministry Of Unification Is Now A Rubber Stamp

The Lee Jae Myung administration has seen a surge in approved contacts with North Korea, but actual communication remains limited.

Korea’s EASY BIO Buys California-Based Nutribins in Push for Global Livestock Nutrition Leadership

EASY BIO acquires Nutribins to strengthen its position in the North American feed additive market, enhancing sustainability and productivity.

Tag: injection

Alteogen Signs $365 Million License Deal With Global Pharma Company for SC Platform Technology

Alteogen has signed an exclusive licensing agreement with a global pharmaceutical company for the development of subcutaneous biopharmaceuticals.

Novo Nordisk’s Weekly Growth Hormone Sogroya Gains Reimbursement in Korea

Novo Nordisk's Sogroya gains insurance coverage, but market changes may be limited due to strong competitors and safety concerns.

Prompt Injection Attacks Are Targeting Corporate AI Agents as AI Security Threats Increase

AI agents are increasingly targeted by cyberattacks, necessitating enhanced security measures and a shift towards AI-driven cybersecurity.

2026’s Game-Changer: Canine Influenza Vaccine “CaniFlu-max” Now Approved for Subcutaneous Injection

A new subcutaneous influenza vaccine for dogs, CaniFlu-max, enhances treatment flexibility and has a strong safety profile.

Alteogen and Biogen: A Game-Changing 200 Million USD License Deal for ALT-B4 Biopharmaceuticals

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

Worried About Your Child’s Height? What Growth Hormone Deficiency Could Mean

A father discovers his child’s height difference is due to growth hormone deficiency, considering treatment options and adherence challenges.

Top News

- Our Sponsors Ad -

Follow us